These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25993185)

  • 21. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
    Morgan SC
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
    PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extraction of
    Großer OS; Wissel H; Wallbaum T; Genseke P; Kupitz D; Ricke J; Ruf J; Amthauer H
    Nuklearmedizin; 2017 Jun; 56(3):69-72. PubMed ID: 28383088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
    Shirley M; McCormack PL
    Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
    Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
    De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
    Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
    Parker C; Zhan L; Cislo P; Reuning-Scherer J; Vogelzang NJ; Nilsson S; Sartor O; O'Sullivan JM; Coleman RE
    Eur J Cancer; 2017 Jan; 71():1-6. PubMed ID: 27930924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.
    Unda-Urzaiz M; Sousa-Campo R; Rodríguez-Antolín A; Silva-Marins C; Juárez-Soto A; Miñana-López B; Figueiredo-de Castro A; Cozar-Olmos JM
    Actas Urol Esp (Engl Ed); 2018 May; 42(4):227-237. PubMed ID: 28711312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
    Jadvar H; Challa S; Quinn DI; Conti PS
    Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
    Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
    Ryan CJ; Saylor PJ; Everly JJ; Sartor O
    Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Sartor O; Appukkuttan S; Weiss J; Tsao CK
    Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.